Rachna Kasliwal

702 total citations
16 papers, 475 citations indexed

About

Rachna Kasliwal is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Rachna Kasliwal has authored 16 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 3 papers in Surgery. Recurrent topics in Rachna Kasliwal's work include Polyomavirus and related diseases (7 papers), Multiple Sclerosis Research Studies (4 papers) and Diabetes Treatment and Management (3 papers). Rachna Kasliwal is often cited by papers focused on Polyomavirus and related diseases (7 papers), Multiple Sclerosis Research Studies (4 papers) and Diabetes Treatment and Management (3 papers). Rachna Kasliwal collaborates with scholars based in United Kingdom, United States and Germany. Rachna Kasliwal's co-authors include Saad Shakir, Lynda V. Wilton, Pei‐Ran Ho, Nolan Campbell, Ih Chang, Tim Spelman, Stephanie Licata, Ludwig Kappos, Heinz Wiendl and María Trojano and has published in prestigious journals such as Neurology, Journal of Neurology Neurosurgery & Psychiatry and Annals of the Rheumatic Diseases.

In The Last Decade

Rachna Kasliwal

15 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rachna Kasliwal United Kingdom 10 210 153 82 77 72 16 475
Lucia Gozzo Italy 15 61 0.3× 74 0.5× 44 0.5× 91 1.2× 52 0.7× 39 664
Sean M. Dawes United States 8 105 0.5× 124 0.8× 230 2.8× 90 1.2× 23 0.3× 14 674
Xuan Qi China 12 55 0.3× 50 0.3× 24 0.3× 151 2.0× 42 0.6× 39 540
Bela Patel United States 11 84 0.4× 21 0.1× 52 0.6× 106 1.4× 25 0.3× 18 440
Zai-Li Zhang China 14 59 0.3× 17 0.1× 48 0.6× 289 3.8× 53 0.7× 31 592
Megan Kane United States 11 27 0.1× 85 0.6× 42 0.5× 259 3.4× 18 0.3× 28 660
Markus A. Schramm Germany 9 91 0.4× 200 1.3× 308 3.8× 116 1.5× 21 0.3× 21 698
Xuejiao Wang China 13 34 0.2× 71 0.5× 13 0.2× 125 1.6× 23 0.3× 56 379

Countries citing papers authored by Rachna Kasliwal

Since Specialization
Citations

This map shows the geographic impact of Rachna Kasliwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachna Kasliwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachna Kasliwal more than expected).

Fields of papers citing papers by Rachna Kasliwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachna Kasliwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachna Kasliwal. The network helps show where Rachna Kasliwal may publish in the future.

Co-authorship network of co-authors of Rachna Kasliwal

This figure shows the co-authorship network connecting the top 25 collaborators of Rachna Kasliwal. A scholar is included among the top collaborators of Rachna Kasliwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachna Kasliwal. Rachna Kasliwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Clowse, Megan E. B., Rebecca Fischer‐Betz, Catherine Nelson‐Piercy, et al.. (2021). POS0022 PHARMACOVIGILANCE PREGNANCY DATA IN A LARGE POPULATION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASE EXPOSED TO CERTOLIZUMAB PEGOL: PREGNANCY OUTCOMES AND CONFOUNDERS. Annals of the Rheumatic Diseases. 80. 213–213. 3 indexed citations
2.
Butzkueven, Helmut, Ludwig Kappos, Heinz Wiendl, et al.. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology Neurosurgery & Psychiatry. 91(6). 660–668. 99 indexed citations
3.
Elkind, Mitchell S.V., Roland Veltkamp, Joan Montaner, et al.. (2020). Natalizumab in acute ischemic stroke (ACTION II). Neurology. 95(8). e1091–e1104. 71 indexed citations
4.
Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 93(15). e1452–e1462. 116 indexed citations
5.
6.
Foley, John, Karleyton C. Evans, Pei‐Ran Ho, et al.. (2019). The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders. 39. 101863–101863. 25 indexed citations
7.
8.
Kappos, Ludwig, Helmut Butzkueven, Tim Spelman, et al.. (2019). Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients. Revue Neurologique. 175. S101–S102. 5 indexed citations
9.
Giovannoni, Gavin, Ludwig Kappos, Joseph R. Berger, et al.. (2019). Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time. Revue Neurologique. 175. S96–S97. 3 indexed citations
10.
Kasliwal, Rachna, Lynda V. Wilton, & Saad Shakir. (2009). Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England. Drug Safety. 32(6). 499–507. 52 indexed citations
11.
Fogg, Carole, Rachna Kasliwal, & Saad Shakir. (2009). Risk Management and Outcomes of Adverse Events to Pioglitazone in Primary Care in the UK. Drug Safety. 32(3). 229–237. 15 indexed citations
12.
Cornelius, Victoria, et al.. (2009). Hypoglycaemia with Oral Antidiabetic Drugs. Drug Safety. 32(5). 409–418. 20 indexed citations
13.
Kasliwal, Rachna, Lynda V. Wilton, & Saad Shakir. (2008). Monitoring the Safety of Pioglitazone. Drug Safety. 31(10). 839–850. 15 indexed citations
14.
Kasliwal, Rachna, et al.. (2007). Safety Profile of Rosuvastatin. Drug Safety. 30(2). 157–170. 30 indexed citations
15.
Kasliwal, Rachna, L. V. Wilton, & Saad Shakir. (2006). Safety Profile of Rosuvastatin as Used in General Practice in England: a Prescription-Event Monitoring Study. Drug Safety. 29(10). 911–1010. 1 indexed citations
16.
Kasliwal, Rachna, Deborah Layton, Scott Harris, Lynda Wilton, & Saad Shakir. (2005). A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational Data. Drug Safety. 28(9). 803–816. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucia Gozzo Breakdown of academic impact, for papers by Sean M. Dawes Breakdown of academic impact, for papers by Xuan Qi Breakdown of academic impact, for papers by Bela Patel Breakdown of academic impact, for papers by Zai-Li Zhang Breakdown of academic impact, for papers by Megan Kane Breakdown of academic impact, for papers by Markus A. Schramm Breakdown of academic impact, for papers by Xuejiao Wang
Rankless by CCL
2026